

Hein Te Riele

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7302865/publications.pdf>

Version: 2024-02-01

46
papers

2,463
citations

304743

22
h-index

302126

39
g-index

47
all docs

47
docs citations

47
times ranked

3003
citing authors

#	ARTICLE	IF	CITATIONS
1	Pro-mutagenic effects of the gut microbiota in a Lynch syndrome mouse model. <i>Gut Microbes</i> , 2022, 14, 2035660.	9.8	5
2	The Widely Used Antihelmintic Drug Albendazole is a Potent Inducer of Loss of Heterozygosity. <i>Frontiers in Pharmacology</i> , 2021, 12, 596535.	3.5	5
3	Three-step site-directed mutagenesis screen identifies pathogenic <i>MLH1</i> variants associated with Lynch syndrome. <i>Journal of Medical Genetics</i> , 2020, 57, 308-315.	3.2	5
4	Warsaw Breakage Syndrome associated DDX11 helicase resolves G-quadruplex structures to support sister chromatid cohesion. <i>Nature Communications</i> , 2020, 11, 4287.	12.8	33
5	WAPL-Dependent Repair of Damaged DNA Replication Forks Underlies Oncogene-Induced Loss of Sister Chromatid Cohesion. <i>Developmental Cell</i> , 2020, 52, 683-698.e7.	7.0	36
6	The RECQL helicase prevents replication fork collapse during replication stress. <i>Life Science Alliance</i> , 2020, 3, e202000668.	2.8	4
7	Extensive trimming of short single-stranded DNA oligonucleotides during replication-coupled gene editing in mammalian cells. <i>PLoS Genetics</i> , 2020, 16, e1009041.	3.5	0
8	Title is missing!. , 2020, 16, e1009041.		0
9	Title is missing!. , 2020, 16, e1009041.		0
10	Title is missing!. , 2020, 16, e1009041.		0
11	Title is missing!. , 2020, 16, e1009041.		0
12	Effective CRISPR/Cas9-mediated correction of a Fanconi anemia defect by error-prone end joining or templated repair. <i>Scientific Reports</i> , 2019, 9, 768.	3.3	18
13	DNA mismatch repair and oligonucleotide end-protection promote base-pair substitution distal from a CRISPR/Cas9-induced DNA break. <i>Nucleic Acids Research</i> , 2018, 46, 2945-2955.	14.5	39
14	Double somatic mutations in mismatch repair genes are frequent in colorectal cancer after Hodgkin's lymphoma treatment. <i>Gut</i> , 2018, 67, 447-455.	12.1	27
15	RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation. <i>PLoS ONE</i> , 2018, 13, e0196979.	2.5	1
16	Loss of p53 suppresses replication-stress-induced DNA breakage in G1/S checkpoint deficient cells. <i>ELife</i> , 2018, 7, .	6.0	34
17	Genomic landscape of retinoblastoma in <i>Rb^{+/+}p130^{+/+}</i> mice resembles human retinoblastoma. <i>Genes Chromosomes and Cancer</i> , 2017, 56, 231-242.	2.8	5
18	Truncation of the MSH2 C-terminal 60 amino acids disrupts effective DNA mismatch repair and is causative for Lynch syndrome. <i>Familial Cancer</i> , 2017, 16, 221-229.	1.9	1

#	ARTICLE	IF	CITATIONS
19	Suspected Lynch syndrome associated MSH6 variants: A functional assay to determine their pathogenicity. <i>PLoS Genetics</i> , 2017, 13, e1006765.	3.5	18
20	Somatic genomic alterations in retinoblastoma beyond RB1 are rare and limited to copy number changes. <i>Scientific Reports</i> , 2016, 6, 25264.	3.3	75
21	Oligonucleotide-directed mutagenesis screen to identify pathogenic Lynch syndrome-associated MSH2 DNA mismatch repair gene variants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 4128-4133.	7.1	28
22	The retinoblastoma protein: multitasking to suppress tumorigenesis. <i>Molecular and Cellular Oncology</i> , 2015, 2, e968062.	0.7	0
23	DNA helicases FANCM and DDX11 are determinants of PARP inhibitor sensitivity. <i>DNA Repair</i> , 2015, 26, 54-64.	2.8	26
24	Loss of photoreceptor and gain of genomic alterations in retinoblastoma reveal tumor progression. <i>EBioMedicine</i> , 2015, 2, 660-670.	6.1	54
25	Temozolomide Increases the Number of Mismatch Repair-Deficient Intestinal Crypts and Accelerates Tumorigenesis in a Mouse Model of Lynch Syndrome. <i>Gastroenterology</i> , 2014, 147, 1064-1072.e5.	1.3	28
26	Tissue-specific mismatch repair protein expression: MSH3 is higher than MSH6 in multiple mouse tissues. <i>DNA Repair</i> , 2013, 12, 46-52.	2.8	33
27	Functional Analysis in Mouse Embryonic Stem Cells Reveals Wild-Type Activity for Three Msh6 Variants Found in Suspected Lynch Syndrome Patients. <i>PLoS ONE</i> , 2013, 8, e74766.	2.5	4
28	Fancc-deficient mice are prone to develop ovarian tumours. <i>Journal of Pathology</i> , 2012, 226, 28-39.	4.5	31
29	Transient suppression of MLH1 allows effective single-nucleotide substitution by single-stranded DNA oligonucleotides. <i>Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis</i> , 2011, 715, 52-60.	1.0	14
30	Characterization of MSH2 variants by endogenous gene modification in mouse embryonic stem cells. <i>Human Mutation</i> , 2011, 32, 389-396.	2.5	17
31	Parameters of oligonucleotide-mediated gene modification in mouse ES cells. <i>Journal of Cellular and Molecular Medicine</i> , 2010, 14, 1657-1667.	3.6	22
32	Loss of Rb proteins causes genomic instability in the absence of mitogenic signaling. <i>Genes and Development</i> , 2010, 24, 1377-1388.	5.9	107
33	Subtle gene modification in mouse ES cells: evidence for incorporation of unmodified oligonucleotides without induction of DNA damage. <i>Nucleic Acids Research</i> , 2010, 38, 6956-6967.	14.5	27
34	Recreating Stem Cells: A Novel Entrance to the Fountain of Youth. <i>Cell Stem Cell</i> , 2009, 4, 279-280.	11.1	3
35	Gene Modification in Embryonic Stem Cells by Single-Stranded DNA Oligonucleotides. <i>Methods in Molecular Biology</i> , 2009, 530, 79-99.	0.9	8
36	Retinoblastoma Teaches a New Lesson. <i>Cell</i> , 2007, 131, 227-229.	28.9	3

#	ARTICLE	IF	CITATIONS
37	Restriction beyond the restriction point: mitogen requirement for G2 passage. <i>Cell Division</i> , 2006, 1, 8.	2.4	9
38	Generation of a mouse mutant by oligonucleotide-mediated gene modification in ES cells. <i>Nucleic Acids Research</i> , 2006, 34, e147-e147.	14.5	46
39	Mitogen requirement for cell cycle progression in the absence of pocket protein activity. <i>Cancer Cell</i> , 2005, 8, 455-466.	16.8	50
40	Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130. <i>Genes and Development</i> , 2004, 18, 2952-2962.	5.9	124
41	Msh2 deficiency does not contribute to cisplatin resistance in mouse embryonic stem cells. <i>Oncogene</i> , 2004, 23, 260-266.	5.9	34
42	Targeted gene modification in mismatch-repair-deficient embryonic stem cells by single-stranded DNA oligonucleotides. <i>Nucleic Acids Research</i> , 2003, 31, 27e-27.	14.5	78
43	Methylation tolerance in mismatch repair proficient cells with low MSH2 protein level. <i>Oncogene</i> , 2002, 21, 2873-2879.	5.9	49
44	Ablation of the Retinoblastoma gene family deregulates G ₁ control causing immortalization and increased cell turnover under growth-restricting conditions. <i>Genes and Development</i> , 2000, 14, 3051-3064.	5.9	385
45	HNPCC-like cancer predisposition in mice through simultaneous loss of Msh3 and Msh6 mismatch-repair protein functions. <i>Nature Genetics</i> , 1999, 23, 359-362.	21.4	199
46	Inactivation of the mouse Msh2 gene results in mismatch repair deficiency, methylation tolerance, hyperrecombination, and predisposition to cancer. <i>Cell</i> , 1995, 82, 321-330.	28.9	777